Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJan 26, 2026
DataAggregated Company Financials
Companies21
  • 7D5.3%
  • 3M15.4%
  • 1Y-31.3%
  • YTD16.7%

The Healthcare industry is up 1.8% in the last week, with Novo Nordisk up 3.2%. Meanwhile, Coloplast actually underperformed within the industry, shrinking 6.2% in the last week. However, the industry is down 31% over the past year. Looking forward, earnings are forecast to grow by 4.7% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 26 Jan 2026DKK 2.3tDKK 453.5bDKK 136.8b18.4x16.7x5x
Wed, 24 Dec 2025DKK 2.0tDKK 453.7bDKK 136.8b17.1x14.4x4.3x
Fri, 21 Nov 2025DKK 1.9tDKK 454.3bDKK 137.1b17x13.9x4.2x
Sun, 19 Oct 2025DKK 2.0tDKK 447.5bDKK 141.7b19x14.4x4.5x
Tue, 16 Sep 2025DKK 2.1tDKK 447.3bDKK 141.6b19.5x14.6x4.6x
Thu, 14 Aug 2025DKK 1.9tDKK 434.8bDKK 132.2b28.8x14.3x4.4x
Sat, 12 Jul 2025DKK 2.5tDKK 423.1bDKK 124.5b30.3x19.9x5.9x
Mon, 09 Jun 2025DKK 2.7tDKK 423.8bDKK 124.7b30.7x21.3x6.3x
Wed, 07 May 2025DKK 2.4tDKK 409.8bDKK 121.1b22.8x20x5.9x
Fri, 04 Apr 2025DKK 2.5tDKK 409.4bDKK 121.3b23.5x20.5x6.1x
Sun, 02 Mar 2025DKK 3.4tDKK 410.1bDKK 121.4b28.6x27.9x8.3x
Tue, 28 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b29.1x29.8x8.6x
Thu, 26 Dec 2024DKK 3.3tDKK 387.4bDKK 111.3b29.8x29.5x8.5x
Sat, 23 Nov 2024DKK 3.9tDKK 387.4bDKK 111.3b31x35x10.1x
Mon, 21 Oct 2024DKK 4.2tDKK 372.1bDKK 107.2b37.1x38.8x11.2x
Wed, 18 Sep 2024DKK 4.6tDKK 371.9bDKK 107.1b36.3x43.1x12.4x
Fri, 16 Aug 2024DKK 4.7tDKK 370.7bDKK 106.9b37.1x44.3x12.8x
Sun, 14 Jul 2024DKK 4.9tDKK 355.2bDKK 106.2b35.5x46.6x13.9x
Tue, 11 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b35.9x46.5x13.9x
Thu, 09 May 2024DKK 4.5tDKK 355.3bDKK 106.5b34.6x42.3x12.7x
Sat, 06 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b37.4x44.7x13x
Mon, 04 Mar 2024DKK 4.4tDKK 340.0bDKK 98.9b38x44.4x12.9x
Wed, 31 Jan 2024DKK 3.9tDKK 320.8bDKK 90.1b31.5x42.8x12x
Fri, 29 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b33.1x40.4x11.3x
Sun, 26 Nov 2023DKK 3.7tDKK 320.5bDKK 90.0b32.8x41.2x11.6x
Tue, 24 Oct 2023DKK 3.5tDKK 305.5bDKK 82.2b27.6x42.9x11.5x
Thu, 21 Sep 2023DKK 3.5tDKK 305.4bDKK 82.2b35.9x42.6x11.5x
Sat, 19 Aug 2023DKK 3.3tDKK 303.2bDKK 81.1b36.8x40.9x10.9x
Mon, 17 Jul 2023DKK 2.9tDKK 286.9bDKK 75.4b39x38.6x10.1x
Wed, 14 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40x39.8x10.5x
Fri, 12 May 2023DKK 3.2tDKK 284.8bDKK 75.0b42.1x42.4x11.2x
Sun, 09 Apr 2023DKK 3.0tDKK 272.4bDKK 68.5b39.4x43.5x10.9x
Tue, 07 Mar 2023DKK 2.8tDKK 292.6bDKK 69.2b39.5x40.6x9.6x
Thu, 02 Feb 2023DKK 2.7tDKK 275.9bDKK 66.3b37.9x40.3x9.7x
Price to Earnings Ratio

40.3x


Total Market Cap: DKK 2.7tTotal Earnings: DKK 66.3bTotal Revenue: DKK 275.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 33.5x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 16.7x which is lower than its 3-year average PE of 33.5x.
  • The 3-year average PS ratio of 9.4x is higher than the industry's current PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 27% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market2.52%
Healthcare5.35%
Pharma6.04%
Biotech4.50%
Healthcare Services4.00%
Medical Equipment0.76%
Life Sciences-0.76%
Healthtech-5.16%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 277x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 103% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 18% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 401.356.3%
+DKK 105.8b		-35.5%PE17.2x
GMAB GenmabDKK 2.13k4.3%
+DKK 5.4b		41.4%PE13.1x
ZEAL Zealand PharmaDKK 426.006.4%
+DKK 1.8b		-44.7%PE4.6x
DEMANT DemantDKK 230.003.1%
+DKK 1.5b		-20.1%PE18.4x
HLUN B H. LundbeckDKK 45.563.4%
+DKK 1.5b		9.8%PE11.9x

Latest News

COLO B
DKK 541.80
Coloplast
7D
-0.2%
1Y
-34.3%

Coloplast A/S' (CPH:COLO B) P/E Is On The Mark

Jan 25
Coloplast A/S' (CPH:COLO B) P/E Is On The Mark
SMSMED
DKK 3.90
Scandinavian Medical Solutions
7D
4.0%
1Y
-29.3%
DEMANT
DKK 230.00
Demant
7D
3.1%
1Y
-20.1%

DEMANT: Stable Guidance And Sector Perform Rating Will Support Future Earnings Resilience

Analysts have reduced their price target on Demant by roughly DKK 2 to about DKK 266, reflecting only modest adjustments to growth, margin and P/E assumptions and citing limited scope for the company to increase its organic revenue share over the medium term. Analyst Commentary Recent research paints a fairly balanced picture for Demant, with the current DKK 250 price target and Sector Perform rating pointing to a view that the shares are reasonably valued on existing growth and margin assumptions.
ALK B
DKK 219.40
ALK-Abelló
7D
-0.6%
1Y
41.4%

Pediatric Allergy Tablets And Food Programs Will Drive A Long Runway Of Opportunity

Catalysts About ALK-Abelló ALK Abelló develops and commercialises allergy immunotherapy tablets, injectable and drop therapies, along with anaphylaxis treatments such as Jext and neffy. What are the underlying business or industry changes driving this perspective?
NOVO B
DKK 401.35
Novo Nordisk
7D
6.3%
1Y
-35.5%

NOVO B: Wegovy Pill Launch And Execution Discipline Will Support Future Upside

Analysts have reduced their fair value estimate for Novo Nordisk to €540 from €612. They cite more moderate assumptions for revenue growth and profit margins, along with a higher discount rate and a slightly higher expected future P/E multiple.
NNIT
DKK 46.20
NNIT
7D
-4.1%
1Y
-52.3%

NNIT: Higher Margins And CEO Transition Will Support Future Upside Potential

Analysts have trimmed their price target on NNIT from DKK 75 to about DKK 62.50, as updated assumptions reflect a higher discount rate, more moderate revenue growth, stronger profit margins, and a lower future P/E multiple. What's in the News CEO Pär Fors has decided to leave NNIT for personal family reasons and will remain in the role until the end of July 2026 or until a new CEO is appointed, whichever comes first (Key Developments).
BAVA
DKK 198.65
Bavarian Nordic
7D
3.2%
1Y
3.4%

BAVA: Vaccine Preparedness Contracts And Buybacks Will Support Stronger Long Term Earnings

Analysts have kept their price target for Bavarian Nordic steady at €250.00. They cite a slightly higher assumed discount rate, a smaller expected revenue decline of around 5%, a higher projected profit margin of about 17%, and a lower future P/E assumption near 23x as key inputs behind the unchanged view.
GMAB
DKK 2,130.00
Genmab
7D
4.3%
1Y
41.4%

GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook

Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.
BRAINP
DKK 0.0024
Brain+
7D
-83.3%
1Y
-97.1%
HLUN B
DKK 45.56
H. Lundbeck
7D
3.4%
1Y
9.8%

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly

Jan 14
H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly
AMBU B
DKK 87.05
Ambu
7D
2.1%
1Y
-36.0%

AMBU B: Share Buybacks And Dividend Policy Will Support Future Upside

Analysts now set Ambu's price target at €139, down from €147, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that adjust their valuation framework. What's in the News Ambu A/S is set to be removed from the OMX Copenhagen 20 Index, which may affect how some index and benchmark focused investors view or hold the stock (Key Developments).
EMBLA
DKK 31.90
Embla Medical hf
7D
-1.2%
1Y
-4.2%

EMBLA: Ukraine Program And Buybacks Will Support Future Margin Stability

Analysts have kept their fair value estimate for Embla Medical hf unchanged at €34.00. They have updated assumptions around discount rate, revenue growth, profit margins and future P/E to reflect a slightly different balance of risk and profitability in their models.
ZEAL
DKK 426.00
Zealand Pharma
7D
6.4%
1Y
-44.7%

ZEAL: Metabolic Collaboration Will Support Future Upside Despite Trimmed Fair Value

Analysts have trimmed their price target on Zealand Pharma to approximately $746 from about $774, citing a slightly higher discount rate and revenue growth headwinds, partially offset by a modestly improved profit margin and a higher assumed future P/E multiple. What's in the News OTR Therapeutics and Zealand Pharma A/S entered into a multi program collaboration and license agreement to discover and develop therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).
GUBRA
DKK 467.00
Gubra
7D
-1.5%
1Y
-27.0%
BIOPOR
DKK 1.01
BioPorto
7D
-4.7%
1Y
-33.4%
CHEMM
DKK 684.00
ChemoMetec
7D
-0.3%
1Y
41.9%